NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

Company Overview

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary anti-infective and anti-inflammatory products. Founded in 2000 and headquartered in Emeryville, California, NovaBay’s core technology platform is based on Aganocide compounds—synthetic molecules designed to mimic the body’s natural defenses against a range of pathogens. These compounds provide targeted antimicrobial action without contributing to antibiotic resistance, positioning NovaBay as a pioneer in innovative infection control solutions.

NovaBay’s product portfolio includes Avenova, an ophthalmic hygiene solution formulated to treat conditions associated with chronic eye inflammation, such as blepharitis and dry eye. Avenova is distributed through both healthcare practitioners and direct-to-consumer channels, enabling broader access to effective eyelid and ocular surface hygiene care. The company also develops NeutroPhase, a sterile wound-care solution employed in hospitals, outpatient clinics, and military settings to promote wound healing and reduce microbial burden without the harsh side effects of traditional antiseptics.

In addition to its flagship products, NovaBay is advancing a pipeline of next-generation topical anti-infective therapies. The company has entered into strategic collaborations and licensing agreements to expand distribution globally, with partnerships spanning North America, Europe, and Asia. These alliances aim to accelerate regulatory approvals and enhance market penetration across ophthalmology, dermatology, and wound care markets, reflecting NovaBay’s commitment to addressing unmet medical needs through science-driven innovation.

Leadership at NovaBay combines deep industry expertise with scientific prowess. Founder and Chairman Dr. Ronald Najafi, a pioneer in antimicrobial research, guided the original development of Aganocide technology. Current President and Chief Executive Officer Fredric Points, M.D., brings extensive experience in pharmaceutical development and commercialization. Under their stewardship, NovaBay continues to leverage its unique platform to develop safe, effective products that strengthen the body’s natural ability to fight infection and inflammation.

Key Stats

• Today's Range: $0.65 to $0.70
• 50-Day Range: $0.55 to $0.69
• 52-Week Range: $0.36 to $2.26
• Volume: 15,680 shs
• Average Volume: 117,507 shs
• Market Capitalization: $3.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.85
• Consensus Rating: Buy

NovaBay Pharmaceuticals Stock Analysis - MarketRank™

NovaBay Pharmaceuticals scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

NovaBay Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

NovaBay Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($3.26) to ($0.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NovaBay Pharmaceuticals has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NBY.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NovaBay Pharmaceuticals does not currently pay a dividend.

Dividend Growth

NovaBay Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for NBY.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for NBY on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.10% of the stock of NovaBay Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 23.25% of the stock of NovaBay Pharmaceuticals is held by institutions.

NBY Stock Analysis - Frequently Asked Questions

How have NBY shares performed this year?

NovaBay Pharmaceuticals' stock was trading at $0.6010 at the beginning of the year. Since then, NBY shares have increased by 10.3% and is now trading at $0.6630.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.32. The firm earned $2.44 million during the quarter, compared to the consensus estimate of $2.50 million. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 7,293.78% and a negative net margin of 102.72%.

When did NovaBay Pharmaceuticals' stock split?

NovaBay Pharmaceuticals's stock reverse split before market open on Friday, May 31st 2024.The 1-35 reverse split was announced on Friday, May 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are NovaBay Pharmaceuticals' major shareholders?

Top institutional investors of NovaBay Pharmaceuticals include C2C Wealth Management LLC (1.69%).
View institutional ownership trends.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Adverum Biotechnologies (ADVM), American Resources (AREC), Clearside Biomedical (CLSD), Hello Group (MOMO), Palatin Technologies (PTN), Xeris Biopharma (XERS) and Algonquin Power & Utilities (AQN).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NBY
• CIK: 1389545
• Web: novabay.com
• Phone: 510-899-8800
• Fax: 510-474-1577
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NovaBay Pharmaceuticals: $0.85
• High Price Target: $0.85
• Low Price Target: $0.85
• Potential Upside/Downside: +28.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($53.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.64 million
• Net Margins: -102.72%
• Pretax Margin: -99.12%
• Return on Equity: -7,293.78%
• Return on Assets: -158.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.15
• Quick Ratio: 0.91

Sales & Book Value

• Annual Sales: $9.78 million
• Price / Sales: 0.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.25 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 5,816,000
• Free Float: 4,881,000
• Market Cap: $3.86 million
• Optionable: Not Optionable
• Beta: 0.44